Fusion Round

Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Cancer Trial

Hamilton, Ontario and Boston. 10 December 2020.  Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the first patient has been dosed in the multi-dose portion of the Phase 1 study evaluating [225Ac]-FPI-1434 (FPI-1434) in patients with advanced solid tumors. FPI-1434 is a radioimmunoconjugate …

Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Cancer Trial Read More »